- Home
- AKBA vs PSTL Comparison
AKBA vs PSTL Comparison
Compare AKBA & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- PSTL
- Stock Information
- Founded
- AKBA 2007
- PSTL 2018
- Country
- AKBA United States
- PSTL United States
- Employees
- AKBA N/A
- PSTL N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- PSTL Real Estate Investment Trusts
- Sector
- AKBA Health Care
- PSTL Real Estate
- Exchange
- AKBA Nasdaq
- PSTL Nasdaq
- Market Cap
- AKBA 336.2M
- PSTL 320.0M
- IPO Year
- AKBA 2014
- PSTL 2019
- Fundamental
- Price
- AKBA $1.93
- PSTL $13.11
- Analyst Decision
- AKBA Strong Buy
- PSTL Strong Buy
- Analyst Count
- AKBA 1
- PSTL 1
- Target Price
- AKBA $7.50
- PSTL $15.50
- AVG Volume (30 Days)
- AKBA 2.1M
- PSTL 144.7K
- Earning Date
- AKBA 11-07-2024
- PSTL 02-24-2025
- Dividend Yield
- AKBA N/A
- PSTL 7.34%
- EPS Growth
- AKBA N/A
- PSTL N/A
- EPS
- AKBA N/A
- PSTL 0.08
- Revenue
- AKBA $169,879,000.00
- PSTL $72,005,000.00
- Revenue This Year
- AKBA N/A
- PSTL N/A
- Revenue Next Year
- AKBA $30.85
- PSTL $12.18
- P/E Ratio
- AKBA N/A
- PSTL $164.87
- Revenue Growth
- AKBA N/A
- PSTL 16.87
- 52 Week Low
- AKBA $0.80
- PSTL $12.77
- 52 Week High
- AKBA $2.48
- PSTL $15.15
- Technical
- Relative Strength Index (RSI)
- AKBA 54.91
- PSTL 34.98
- Support Level
- AKBA $1.74
- PSTL $12.77
- Resistance Level
- AKBA $1.90
- PSTL $13.91
- Average True Range (ATR)
- AKBA 0.08
- PSTL 0.24
- MACD
- AKBA -0.01
- PSTL -0.06
- Stochastic Oscillator
- AKBA 54.44
- PSTL 30.07
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.